- Chef de Clinique
Dr. Peter von dem Borne studied Medicine at the University of Utrecht. He performed PhD research in the Laboratory for Thrombosis and Hemostasis of the Department of Hematology in the University Medical Center Utrecht. The title of his thesis was ‘the role of factor XI in blood coagulation and fibrinolysis’ (1996). Between 1996 and 2002 he was in training for Internal Medicine in the Eemland Hospital in Amersfoort and the University Medical Center Utrecht, which was followed by 2 year specialized training in Hematology and Stem cell transplantation in both the University Medical Center Utrecht and the Leiden University Medical Center. He was certified in Internal Medicine in 2002, in Hematology in 2004 and was appointed a staff member of the Department of Hematology in 2005. In 2006 he became Head of the Hematological Clinic and coordinator of the clinical stem cell transplantation program. He is a member of the Dutch Society of Hematology (NVvH), the European Haematology Association (EHA) and the American Society of Hematology (ASH).
His research is focused on three different topics:
- Clinical stem cell transplantation. This involves development and implementation of new indications for stem cell transplantation (transplantation of elderly patients, benign hematological disorders, auto-immune disorders) and analysis of the results of stem cell transplantations.
- Optimization of donor lymphocyte infusion after allogeneic stem cell transplantation. Retrospective analysis of the results of donor lymphocyte infusion in order to optimize dosing schedules towards maximal clinical effects with minimal Graft-versus-Host-Disease toxicity.
- Elucidation of the pathogenetic mechanism of Graft-versus-Host Disease (GvHD). This involves immunohistochemic analysis of biopsies from skin with GvHD and analysis of the interaction of cytotoxic T cells with non-hematopoietic tissues or cells derived from GvHD target organs.
- Willemze AJ, Bakker AC, von dem Borne PA, Bajema IM, Vossen JM. The effect of graft-versus-host disease on skin endothelial and epithelial cell chimerism in stem-cell transplant recipients. Transplantation. 2009; 87:1096-1101
- von dem Borne PA, Starrenburg CW, Barge RM, Marijt EW, Falkenburg JH, Willemze R. Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen. Bone Marrow Transplant 2008; 42:137-138
- Griffioen M, van der Meijden ED, Slager EH, Honders MW, Rutten CE, van Luxemburg-Heijs SA, von dem Borne PA, van Rood JJ, Willemze R, Falkenburg JH. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci U S A. 2008; 105: 3837-3842
- von dem Borne PA, Beaumont F, Starrenburg CW, Oudshoorn M, Hale G, Falkenburg JH, Fibbe WE, Willemze R, Barge RM. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica. 2006; 91: 1559-1562
- von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Jedema I, Mulder A, Willemze R, Falkenburg JH. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia 2006; 20: 1040-1046
Leids Universitair Medisch Centrum
2333 ZA Leiden
Tel: +31 71 526 2271
2300 RC Leiden